NASDAQ · SILK
Healthcare · Medical - Devices
$27.49
Down-$0.01 (-0.04%)
Updated Aug 15, 2026, 3:58 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SILK does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SILK.
SILK research
Company profile and research snapshot.
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 17, 2024 | Stifel | Hold | — |
| Jul 11, 2024 | Argus Research | Sell | — |
| Jun 18, 2024 | Lake Street | Hold | — |
| May 1, 2024 | JP Morgan | Neutral | — |
| May 1, 2024 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 21, 2024
Monteverde & Associates PC is investigating the proposed merger between Silk Road Medical, Inc. and Boston Scientific Corporation, where Silk Road stockholders will receive $27.50 in cash per share. The shareholder vote is scheduled for September 5, 2024.
GlobeNewswire Inc. · Apr 30, 2024
Please call me to verify details of the release at 978-460-7074
GlobeNewswire Inc. · Apr 23, 2024
SUNNYVALE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference.
Zacks Investment Research · Apr 23, 2024
Silk Road Medical (SILK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SILK.
No results
No recent SID articles mention SILK.
